Fierce Pharma
NOVEMBER 3, 2023
Pfizer’s plunging COVID-19 product demand has spurred a companywide cost-cutting campaign, with nearly 200 jobs now on the chopping block in Michigan. | Pfizer is cutting roughly 200 positions at its Kalamazoo site following a review of demand for its COVID-19 vaccine and antiviral Comirnaty and Paxlovid.
MedCity News
NOVEMBER 3, 2023
A new Duke study shows that KelaHealth’s platform was associated with a 21% reduction in acute kidney injury and a 24% decrease in costly readmissions following colorectal surgery. The platform delivers insights about individual patients’ surgical risks and what their care journeys should look like.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 3, 2023
Bausch Health’s gastroenterology unit Salix Pharmaceuticals has chalked up a win in its long-running fight to fend off a generic to its irritable bowel syndrome diarrhea (IBD-D) med Xifaxan. | The D.C. federal court denied Alvogen's bid to force the FDA to grant full approval to its proposed Xifaxan generic. The agency previously gave the generic a tentative approval before some patents expire in 2029.
MedCity News
NOVEMBER 3, 2023
Changes in HHS structure, along with well-funded and staffed partners at the state, local, tribal and territorial levels, may prove helpful for success during future public health emergencies and can help earn and maintain the public’s trust.
Fierce Pharma
NOVEMBER 3, 2023
In its attempt to win approval in the United States for its groundbreaking T-cell therapy Ebvallo (tabelecleucel), Atara Biotherapeutics is turning to the same partner it used to gain a green light | In its attempt to win approval in the United States for its groundbreaking T-cell therapy Ebvallo, Atara Biotherapeutics is turning to the same partner it used to gain a green light in Europe—Pierre Fabre Laboratories.
MedCity News
NOVEMBER 3, 2023
This article delves into the importance of audience segmentation, offers guidance on identifying distinct audience groups, and discusses influential personas in healthcare.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 3, 2023
The gene therapy programs of Lexeo Therapeutics span rare forms of cardiomyopathy and certain types of Alzheimer’s disease. But Lexeo’s IPO comes as a rival gene therapy developer sues the biotech, claiming its work employs stolen trade secrets.
Fierce Pharma
NOVEMBER 3, 2023
Holding more than 25 years of experience in the medical sector spread across numerous pharmaceutical and CRO-based clinical research roles, Edel Shaw knows a thing or two about drug development.
PharmaTech
NOVEMBER 3, 2023
Pharmaceutical Technology Europe® spoke with Gustavo Ferrer from Dr. Ferrer BioPharma, a US company focused on innovative intranasal medications, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.
PharmExec
NOVEMBER 3, 2023
Due to a global demand, treatments such as Adderall and Ritalin have been in short supply for the management of attention-deficit hyperactivity disorder.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
NOVEMBER 3, 2023
Amid the unwinding of the continuous enrollment provision, more than 10 million people have lost Medicaid coverage, according to data from KFF. Of those disenrolled from Medicaid coverage, 71% were removed from coverage for procedural reasons.
European Pharmaceutical Review
NOVEMBER 3, 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Pfizer’s Litfulo (ritlecitinib) for treatment for severe alopecia areata in patients 12 years and older. A hard capsule medicine, Litfulo is recommended to be taken daily as one 50mg oral dose. Litfulo’s active ingredient, ritlecitinib, is an enzyme inhibitor. It works irreversibly and selectively inhibits Janus kinase 3 (JAK3) and the tyrosine (TEC) family of kinases by blocking γ-common cytokine signalling and reduc
PharmaTimes
NOVEMBER 3, 2023
Since 2022, an estimated 17,000 strokes and 4,000 deaths have been prevented - News - PharmaTimes
Copyright Clearance Center
NOVEMBER 3, 2023
KDP authors can now choose from a selection of AI-generated narrators to create a machine-generated audiobook.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaTimes
NOVEMBER 3, 2023
Over 63,000 cancer cases were diagnosed between one and five years after referral - News - PharmaTimes
PharmExec
NOVEMBER 3, 2023
The newly approved Alinity m high risk human papillomavirus (HPV) assay is indicated to detect HPV and for use in routine cervical cancer screening per professional medical guidelines.
PharmaTech
NOVEMBER 3, 2023
Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, recommends some key issues that pharma manufacturers should consider when formulating products that require a medical device.
PharmExec
NOVEMBER 3, 2023
Ongoing phase 1 dose-escalation trial of KO-2806 (FIT-001) for the treatment of patients with KRASG12C-mutated non-small cell lung cancer expected to begin dosing patients in combination with adagrasib by mid-2024.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Referral MD
NOVEMBER 3, 2023
How the Healthcare Digital Front Door Improves Office Efficiency In recent years, the healthcare industry has undergone a transformation driven by digital technologies. One significant aspect of this transformation is implementing a healthcare digital front door. The digital front door refers to the virtual entry point that connects patients with healthcare providers, allowing them to access services and communicate with their healthcare team online.
Legacy MEDSearch
NOVEMBER 3, 2023
POLARIS AR is pleased to announce today that their STELLAR Knee has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). STELLAR Knee is the first clearance for POLARIS AR , a company focused on creating a new category in Mixed Reality surgical guidance. POLARIS AR and STELLAR Knee are building the intersection of physical surgery and virtual surgical guidance, bringing about a one-of-a-kind digital operating room environment.
PharmaTech
NOVEMBER 3, 2023
Hollie Barton, senior director, Chromatographic Services, for the PPD clinical research business of Thermo Fisher Scientific, highlights one approach to ensuring the continuation of analytical expertise.
Pharmaceutical Technology
NOVEMBER 3, 2023
The large amendment to Poland’s Reimbursement Act (Duża Nowelizacja Ustawy Refundacyjnej, DNUR) finally came into legal force on November 1, although a small number of its regulations will only come into force in 2024 and 2025.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaTech
NOVEMBER 3, 2023
Pharmaceutical Technology Europe® spoke with Leonardo Vincenzi from CONTINUUS Pharmaceuticals, a US company that specializes in process development, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.
pharmaphorum
NOVEMBER 3, 2023
Study finds higher cancer rate in patients given ‘all clear’ Phil.
Pharmaceutical Technology
NOVEMBER 3, 2023
Driven by success of recent GLP1R-targeting drugs, there has been a surge in the number of active pipeline drugs addressing this target for type 2 diabetes.
Pharmaceutical Commerce
NOVEMBER 3, 2023
With new tech acquisition, the software company also introduces a new branded AI assistant for mobile devices specifically for the life sciences sector.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
NOVEMBER 3, 2023
In May 2022, Terremoto raised $75m on Series A financing for its lysine-based covalency drug development platform.
PharmaVoice
NOVEMBER 3, 2023
From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.
Pharmaceutical Technology
NOVEMBER 3, 2023
The European Commission (EC) has approved Gedeon Richter and Sumitomo Pharma’s Type II Variation application for RYEQO for endometriosis.
Pharmacy Times
NOVEMBER 3, 2023
It is crucial to continue to evolve from dependent prescribing to an independent model, and address barriers with opportunities for change.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
352 
Let's personalize your content